Andere Sprachen Cipla Limited

Aktien

A0B5L5

INE059A01026

CIPLA

Pharmazeutika

Markt geschlossen - NSE India S.E. Andere Börsenplätze 13:05:07 05.06.2026			% 5 Tage	Veränd. 1. Jan.
1.401,30 ^INR	+0,19 %		+0,02 %	-7,28 %

22.05.	Indiens Sun Pharma übertrifft Gewinnerwartungen dank Nachfrage nach Spezialmedikamenten, Aktienkurs gibt wegen Kostendrucks nach	RE
14.05.	CIPLA LIMITED : Phillip Securities gibt eine Verkaufsbewertung ab	ZM

Andere Sprachen

22.05.	India's Sun Pharma posts profit beat on specialty drug demand, shares slide on cost pressures
14.05.	Cipla Limited announces Annual dividend, payable on July 25, 2026
13.05.	Cipla Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
13.05.	Indian drugmaker Cipla misses Q4 profit view on weak US sales
13.05.	Cipla Q4 consol net profit 5.55 billion rupees
13.05.	Cipla Limited Appoints Sushrut Kulkarni as President & Global Chief - Integrated Product Development, Effective from May 18, 2026
13.05.	Indian drugmaker Cipla's fourth-quarter profit misses view on weak US sales
06.05.	Cipla Limited Launches Ciposcillo Advanced Oscillometer for Respiratory Diagnostics
28.04.	Pfizer secures deals to keep heart drug free of generic rivals until 2031
28.04.	Pfizer reaches settlement agreements with Dexcel Pharma, Hikma & Cipla for Vyndamax
28.04.	Pfizer Settles With Three Drug Manufacturers Over Alleged Patent Infringement
24.04.	Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA
23.04.	Cipla Limited Announces U.S. Fda Approval for First Ab-Rated Generic of Ventolin Hfa
23.04.	Indian Equities Extend Losses on Thursday as Banking Sell-Off, Crude Oil Surge Weigh
23.04.	Cipla Arm Gets US FDA's Final Nod for Albuterol Sulfate Inhalation Aerosol; Shares Up 3%
23.04.	Cipla receives US FDA approval for first AB-rated generic of Ventolin HFA
17.04.	Cipla's manufacturing facility in Goa undergoes US FDA inspection
15.04.	Tejas Networks Limited Announces Resignation of P R Ramesh as Independent Director, Effective on April 18, 2026 and Appointment of Preetham Uthaiah as Chief Operating Officer, Effective April 15, 2026
03.04.	Cipla expands U.S. respiratory portfolio with approval of nintedanib capsules (100mg & 150mg) for idiopathic pulmonary fibrosis
30.03.	Cipla Limited Announces Global Chief Executive Officer Changes, Effective April 1, 2026
30.03.	Cipla Limited Announces Appointment of Senior Management Personnel of the Company Effective 1 April, 2026
19.03.	Cipla approved investment up to USD 100 million in equity share capital of Cipla (EU) Limited
19.03.	Cipla Limited Approves Investment Up to Usd 100 Million in the Equity Share Capital of Cipla (Eu) Limited
19.03.	Cipla Limited Announces Changes to Its Board
16.03.	Fennec Pharmaceuticals announces settlement agreement resolving Pedmark patent litigation